HIV 感染患者中磺胺嘧啶 BID 与 QID 给药的药代动力学-猫眼课题宝

HIV 感染患者中磺胺嘧啶 BID 与 QID 给药的药代动力学

批准号：

6103663

负责人：

STEPHEN PISCITELLI

金额：

$0.0万

依托单位：

CLINICAL CENTER

依托单位国家：

美国

项目类别：

财政年份：

资助国家：

美国

项目状态：

未结题

起止时间：

至

来源：

https://reporter.nih.gov/project-details/6103663

关键词：

AIDS therapy HIV infections clinical research dosage drug screening /evaluation human subject pharmacokinetics sulfanilamides

项目摘要

项目成果

STEPHEN PISCITELLI的其他基金

相似基金

相关文献

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

This study is an open-label, randomized, cross-over study to compare the pharmacokinetics of sulfadiazine given on a twice daily or four times daily schedule. Ten human immunodeficiency virus-infected patients with CD4 counts below 500 will be enrolled. Patients must not have concurrent opportunistic infections and must be willing to comply with the study regimen. The study is designed to compare pharmacokinetic parameters and serum concentrations of sulfadiazine at two doses: 1000mg QID and 2000mg BID. Additionally, this study will assess the safety and tolerability of these dosage regimens. Currently, the study has received IRB approval and will begin enrolling within the next 1 to 2 months.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文